Unique lipoprotein phenotype and genotype associated with exceptional longevity.

CONTEXT Individuals with exceptional longevity have a lower incidence and/or significant delay in the onset of age-related disease, and their family members may inherit biological factors that modulate aging processes and disease susceptibility. OBJECTIVE To identify specific biological and genetic factors that are associated with or reliably define a human longevity phenotype. DESIGN, SETTING, AND PARTICIPANTS In a case-control design, 213 Ashkenazi Jewish probands with exceptional longevity (mean [SD] age, 98.2 [5.3] years) and their offspring (n = 216; mean [SD] age, 68.3 [6.7] years) were recruited from 1998 to 2002, while an age-matched control group of Ashkenazi Jews (n = 258) and participants from the Framingham Offspring Study (n = 589) were accepted as control groups. MAIN OUTCOME MEASURES Detailed questionnaires, physical examination, and blood samples were taken, including assessment of lipids and lipoprotein subclass levels and particle sizes by proton nuclear magnetic resonance. Samples were also genotyped for the codon 405 isoleucine to valine (I405V) variation in the cholesteryl ester transfer protein (CETP) gene, which is involved in regulation of lipoprotein and its particle sizes. RESULTS High-density lipoprotein (HDL) and low-density lipoprotein (LDL) particle sizes were significantly higher in probands compared with both control groups (P =.001 for both), independent of plasma levels of HDL and LDL cholesterol and apolipoprotein A1 and B. This phenotype was also typical of the proband's offspring but not of the age-matched controls. The HDL and LDL particle sizes were significantly larger in offspring and controls without hypertension or cardiovascular disease, (P =.001 and P =.008, respectively). Furthermore, lipoprotein particle sizes, but not plasma LDL levels, were significantly higher in offspring and controls without the metabolic syndrome (P<.001). Probands and offspring had a 2.9- and 3.6-fold (in men) and 2.7- and 1.5-fold (in women) increased frequency, respectively, of homozygosity for the 405 valine allele of CETP (VV genotype), respectively, compared with controls (P<.001 for both). Those probands with the VV genotype had increased lipoprotein sizes and lower serum CETP concentrations. CONCLUSIONS Individuals with exceptional longevity and their offspring have significantly larger HDL and LDL particle sizes. This phenotype is associated with a lower prevalence of hypertension, cardiovascular disease, the metabolic syndrome, and increased homozygosity for the I405V variant in CETP. These findings suggest that lipoprotein particle sizes are heritable and promote a healthy aging phenotype.

[1]  M. Austin Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype , 2000, Current atherosclerosis reports.

[2]  S. Yamashita,et al.  Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency , 1995, European journal of clinical investigation.

[3]  Revisiting the role of fat mass in the life extension induced by caloric restriction. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[5]  W. Kraus,et al.  Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[6]  E. Schaefer,et al.  Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients DOI 10.1194/jlr.M200037-JLR200 , 2002, Journal of Lipid Research.

[7]  P. Wilson,et al.  Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. , 1994, Journal of lipid research.

[8]  K. Okumura,et al.  Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. , 2002, Atherosclerosis.

[9]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[10]  D. Rader,et al.  Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. , 1995, The Journal of clinical investigation.

[11]  G. Rennert,et al.  Clinical Phenotype of Families with Longevity , 2004, Journal of the American Geriatrics Society.

[12]  I. Gabriely,et al.  Plasma HDL levels highly correlate with cognitive function in exceptional longevity. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  P. Libby Managing the risk of atherosclerosis: the role of high-density lipoprotein. , 2001, The American journal of cardiology.

[14]  A. Tall,et al.  Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. , 1998, Journal of lipid research.

[15]  S. Yamashita,et al.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. , 1990, The Journal of clinical investigation.

[16]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[17]  Carney,et al.  BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer. , 1997, Medscape women's health.

[18]  R. Krauss,et al.  Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein , 1999, Nature Medicine.

[19]  A. Shuldiner,et al.  Searching for human longevity genes: the future history of gerontology in the post-genomic era. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[20]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[21]  A. Rantala,et al.  Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima‐media thickness , 2001, European journal of clinical investigation.

[22]  T. Arai,et al.  Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[23]  D. Rader,et al.  Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. , 2000, Molecular medicine today.

[24]  D. Falconer,et al.  Introduction to Quantitative Genetics. , 1962 .

[25]  J. Hokanson,et al.  Complex segregation analysis of LDL peak particle diameter , 1993, Genetic epidemiology.

[26]  S. Grundy,et al.  Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. , 1999, Journal of lipid research.

[27]  P. Ridker,et al.  Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.

[28]  R. Krauss,et al.  Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. , 1992, Clinical chemistry.

[29]  M. Regan,et al.  What does it take to live to 100? , 2002, Mechanisms of Ageing and Development.

[30]  A. Reunanen,et al.  Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men , 2000, European journal of clinical investigation.

[31]  M J Malloy,et al.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk. , 1999, Genome research.

[32]  V. Gudnason,et al.  Cholesteryl ester transfer protein gene effect on CETP activity and plasma high‐density lipoprotein in European populations , 1999, European journal of clinical investigation.

[33]  J. Després,et al.  HDL particle size: a marker of the gender difference in the metabolic risk profile. , 2002, Atherosclerosis.

[34]  J. Boer,et al.  Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Johnf . Thompson,et al.  Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R200018-JLR200 , 2003, Journal of Lipid Research.

[36]  L. Kunkel,et al.  Life-long sustained mortality advantage of siblings of centenarians , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Yokoyama,et al.  Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. , 2001, Atherosclerosis.

[38]  Herman Buschke,et al.  Abnormality of gait as a predictor of non-Alzheimer's dementia. , 2002, The New England journal of medicine.

[39]  H. Inagaki,et al.  Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity , 2003, Journal of Molecular Medicine.

[40]  J. Sorkin,et al.  Offspring of Centenarians Have a Favorable Lipid Profile , 2001, Journal of the American Geriatrics Society.

[41]  T C Matise,et al.  A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4 , 2001, Proceedings of the National Academy of Sciences of the United States of America.